Myosin Therapeutics, a Florida-based biotechnology company, announced on Tuesday that it has been awarded USD2m in funding from the Florida Department of Health through the Casey DeSantis Florida Cancer Innovation Fund (FCIF).

This funding is intended to support the company's STAR-GBM Phase 1/2 clinical trial evaluating MT-125 in patients newly diagnosed with glioblastoma (GBM).

Myosin Therapeutics was selected for funding based on the scientific innovation and clinical potential of MT-125, its lead oncology therapeutic candidate. The award will specifically support clinical trial activities being conducted at the Mayo Clinic campus in Jacksonville, Florida.

The Phase 1/2 STAR-GBM clinical trial represents the first clinical evaluation of MT-125 and is being conducted in collaboration with Mayo Clinic, with all three Mayo Clinic clinical research units in the United States participating in the study. The Phase 1 portion of the trial will evaluate safety, tolerability, and pharmacokinetics, while generating early clinical data to inform the Phase 2 dose expansion portion of the study.